Syndax Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $12,500 | $3,500 | $0 | $536 |
Gross Profit | 12,498 | -40,837 | -3 | 268 |
EBITDA | -84,101 | -68,015 | -72,342 | -72,407 |
EBIT | -84,103 | -68,018 | -72,345 | -72,410 |
Net Income | -84,126 | -68,063 | -72,400 | -72,473 |
Net Change In Cash | 12,500 | 3,500 | 0 | 536 |
Free Cash Flow | -62,322 | -71,645 | -83,548 | -41,349 |
Cash | 133,019 | 105,396 | 114,615 | 295,394 |
Basic Shares | 85,433 | 85,274 | 85,213 | 72,520 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $126,576 | $139,709 | $1,517 |
Gross Profit | -12 | -454 | 139,709 | 1,517 |
EBITDA | -229,942 | -151,724 | 26,263 | -71,334 |
EBIT | -229,954 | -151,757 | 26,220 | -71,423 |
Net Income | -209,360 | -143,749 | 24,926 | -73,069 |
Net Change In Cash | 0 | 126,576 | 139,709 | 1,517 |
Cost of Revenue | 106,722 | 90,634 | ||
Free Cash Flow | -160,601 | -133,900 | 29,002 | -71,260 |
Cash | 295,394 | 74,356 | 221,965 | 115,243 |
Basic Shares | 70,370 | 60,760 | 53,622 | 41,308 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.98 |
2024-06-30 | -$0.80 |
2024-03-31 | -$0.85 |
2023-12-31 | -$1 |
